modelA03DA04

Diagram of A03DA04

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:CicloniumAndAnalgesics
ATC code:A03DA04
route:oral
compartments:1
dosage:20mg
volume of distribution:1.5L
clearance:6L/h
other parameters in model implementation

Ciclonium is an antispasmodic drug belonging to the class of quaternary ammonium compounds, used in combination with analgesics for the treatment of gastrointestinal spasms and related pain. It acts by inhibiting muscarinic receptors leading to smooth muscle relaxation. This ATC code refers to fixed-dose combinations of ciclonium with analgesic agents. Ciclonium is an older drug, not widely used or approved in many countries today.

Pharmacokinetics

No published human pharmacokinetic studies found; values below are model estimates based on the profile of similar quaternary ammonium antispasmodics administered orally in adults.

References

  1. Lugo, RA, & Kern, SE (2004). The pharmacokinetics of oxycodone. Journal of pain & palliative care pharmacotherapy 18(4) 17–30. DOI:10.1300/j354v18n04_03 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15760805

  2. Moore, RA, et al., & Straube, S (2015). Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. British journal of clinical pharmacology 80(3) 381–388. DOI:10.1111/bcp.12628 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25784216

  3. Thigpen, JC, et al., & Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. European journal of drug metabolism and pharmacokinetics 44(5) 591–609. DOI:10.1007/s13318-019-00552-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31006834

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)